

**Claims**

1. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising the steps of
  - i) contacting a test compound with a FPRL2 polypeptide,
  - ii) detect binding of said test compound to said FPRL2 polypeptide.
2. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising the steps of
  - i) determining the activity of a FPRL2 polypeptide at a certain concentration of a test compound or in the absence of said test compound,
  - ii) determining the activity of said polypeptide at a different concentration of said test compound.
3. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising the steps of
  - i) determining the activity of a FPRL2 polypeptide at a certain concentration of a test compound,

- ii) determining the activity of a FPRL2 polypeptide at the presence of a compound known to be a regulator of a FPRL2 polypeptide.
- 5      4.      The method of any of claims 1 to 3, wherein the step of contacting is in or at the surface of a cell.
- 5.      The method of any of claims 1 to 3, wherein the cell is in vitro.
- 10      6.      The method of any of claims 1 to 3, wherein the step of contacting is in a cell-free system.
- 7.      The method of any of claims 1 to 3, wherein the polypeptide is coupled to a detectable label.
- 15      8.      The method of any of claims 1 to 3, wherein the compound is coupled to a detectable label.
- 20      9.      The method of any of claims 1 to 3, wherein the test compound displaces a ligand which is first bound to the polypeptide.
- 10.      The method of any of claims 1 to 3, wherein the polypeptide is attached to a solid support.
- 25      11.      The method of any of claims 1 to 3, wherein the compound is attached to a solid support.
- 30      12.      A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising the steps of

- i) contacting a test compound with a FPRL2 polynucleotide,
- ii) detect binding of said test compound to said FPRL2 polynucleotide.

5      13.      The method of claim 12 wherein the nucleic acid molecule is RNA.

14.      The method of claim 12 wherein the contacting step is in or at the surface of a cell.

10      15.      The method of claim 12 wherein the contacting step is in a cell-free system.

16.      The method of claim 12 wherein polynucleotide is coupled to a detectable label.

15      17.      The method of claim 12 wherein the test compound is coupled to a detectable label.

18.      A method of diagnosing a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-  
20      urinary diseases, cancer and respiratory diseases in a mammal comprising the steps of

i)      determining the amount of a FPRL2 polynucleotide in a sample taken from said mammal,

25

ii)      determining the amount of FPRL2 polynucleotide in healthy and/or diseased mammals.

19.      A pharmaceutical composition for the treatment of a disease comprised in a  
30      group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory

diseases in a mammal comprising a therapeutic agent which binds to a FPRL2 polypeptide.

5           20.    A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising a therapeutic agent which regulates the activity of a FPRL2 polypeptide.

10          21.    A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising a therapeutic agent which regulates the activity of a FPRL2 polypeptide, wherein said therapeutic agent is

15

- i)       a small molecule,
- ii)      an RNA molecule,
- iii)     an antisense oligonucleotide,
- iv)      a polypeptide,

20          v)      an antibody, or

vi)      a ribozyme.

22.    A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising a FPRL2 polynucleotide.

25

23.    A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising a FPRL2 polypeptide.

30

24. Use of regulators of a FPRL2 for the preparation of a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal.
- 5
25. Method for the preparation of a pharmaceutical composition useful for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising the steps of
- 10
- i) identifying a regulator of FPRL2,
  - ii) determining whether said regulator ameliorates the symptoms of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal; and
  - iii) combining of said regulator with an acceptable pharmaceutical carrier.
- 15
26. Use of a regulator of FPRL2 for the regulation of FPRL2 activity in a mammal having a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases.
- 20